Avacta Group (LSE:AVCT) Tariff Resilience Score: 5/10 (As of Jul. 03, 2026)


LSE:AVCT Avacta Group PLC LSE:AVCT
28 GF Score
Price £0.73
GF Value £0.49
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Avacta Group Tariff Resilience Score?

Avacta Group LSE:AVCT -1.49% 28 Tariff Resilience Score is 5 as of Jul. 03, 2026. GuruFocus rates LSE:AVCT with a GF Score™ of 28/100 and a GF Value™ of £0.49 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 1,373 Biotechnology companies, Avacta Group ranks better than 62.27% on this metric.

Avacta Group has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Avacta Group has Avacta Group's exposure is balanced by its diversified biotech portfolio. While it imports raw materials, its primary markets are in Europe, which may shield it from US-China tariffs. Historical impacts have been minimal, but limited pricing power poses a risk.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Avacta Group might have Average Resilient.

Avacta Group  (LSE:AVCT) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Avacta Group Tariff Resilience Score Related Terms

LSE:AVCT vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Avacta Group's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avacta Group Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avacta Group's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Avacta Group's Tariff Resilience Score falls into.


LSE:AVCT
28GF Score
Avacta Group PLC LSE:AVCT
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Avacta Group (LSE:AVCT) has a Tariff Resilience Score of 5 as of Jul. 03, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Avacta Group ranks #518 out of 1373 companies in the Biotechnology industry, placing it in the top 37.7%.
Is Avacta Group's Tariff Resilience Score too high?
Avacta Group's current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Avacta Group's value of 5 is 25% above this industry median. Based on the distribution chart, Avacta Group ranks #518 out of 1373 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Avacta Group has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avacta Group's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avacta Group ranks #518 out of 1373 companies for Tariff Resilience Score. This puts Avacta Group in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Avacta Group's value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,373 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avacta Group's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avacta Group's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avacta Group stock overvalued right now?
Based on GuruFocus' analysis, Avacta Group (LSE:AVCT) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.49, compared to a current price of £0.73 — trading 48% above its estimated fair value. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Avacta Group's overall GF Score™ is 28/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Avacta Group (LSE:AVCT), the current Tariff Resilience Score is 5 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Avacta Group (LSE:AVCT) Overvalued in 2026?

Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued. The current stock price of £0.73 is trading 48% above its estimated GF Value™ of £0.49. GuruFocus considers Avacta Group to be Significantly Overvalued.

Key valuation signals for LSE:AVCT:

  • Tariff Resilience Score: 5
  • GF Value™: £0.49 vs. price of £0.73 (48% above fair value)
  • GF Score™: 28/100 with 9 warning signs
  • Industry Position: 25% above the Biotechnology median (#518 of 1373)

No single metric tells the full story. See the LSE:AVCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Avacta Group Business Description

Other Exchanges AVCTF:USARTQ1:Germany
Address 58 Wood Lane, White City Imperial College Campus, Scale Space, London, GBR, W12 7RZ
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
28GF Score

Get the complete analysis for LSE:AVCT

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.73
Price
£0.49
GF Value